MOSCOW, March 1 – RIA Novosti. The Argentine government is interested in gaining access to Russian vaccines against COVID-19 EpiVacCorona and CoviVac, adviser to the country's president Cecilia Nicolini said in an interview with RIA Novosti following her visit to Moscow.
“It is obvious that we are interested in access to these vaccines, if there is such an opportunity,” Nicolini said in response to a question about the Argentinean side's interest in vaccines against COVID-19 developed by the Novosibirsk Vector Center and the Chumakov Center of the Russian Academy of Sciences.
According to Cecilia Nicolini, in Argentina they trust the technological development and science of Russia, and this is why they believed in the Sputnik V vaccine in the first place.
“Other developments will certainly be just as high-quality, so if they are available and we can access the information our regulator needs for approval and acquisition, and if more vaccines are needed in the vaccination strategy that the Minister of Health defines,” we will undoubtedly keep them in mind, “added Nicolini.
Earlier, Russia and Argentina signed a memorandum of understanding aimed at opening production of the Sputnik V coronavirus vaccine in a Latin American country. Sputnik V was also registered in Argentina under the accelerated procedure, and vaccination with this drug is already underway in the country.
In August, the Russian Ministry of Health registered the world's first vaccine for the prevention of COVID-19, developed by the Gamaleya Research Center for Electrochemistry. It was named “Sputnik V”. The vaccine is based on a well-studied and validated human adenoviral vector platform, the important benefits of which are safety, efficacy and no long-term adverse effects. Also in Russia, two more vaccines against COVID-19 have been created – this is a vaccine from the Vector Center of the Rospotrebnadzor EpiVacCorona and the KoviVac vaccine developed by the Chumakov Center of the Russian Academy of Sciences.